Neumora Therapeutics(US:NMRA)2025-03-03 12:06Financial Performance - Neumora reported a net loss of $58.8 million for Q4 2024, compared to a net loss of $108.7 million for the same period in 2023, indicating a 46% improvement[13]. - Neumora's total operating expenses for the full year 2024 were $263.5 million, compared to $252.1 million for 2023, marking a 5% increase[15]. - General and administrative expenses for Q4 2024 were $17.0 million, up from $11.2 million in Q4 2023, representing a 52% increase[13]. Research and Development - Research and development expenses for Q4 2024 were $45.9 million, up from $38.9 million in Q4 2023, reflecting a 18% increase[13]. - The Phase 1b study for NMRA-511 in Alzheimer's disease agitation is on track to report data by the end of 2025[7]. - Neumora plans to report topline data from the KOASTAL-3 study in Q1 2026 and from KOASTAL-2 in Q2 2026[5]. - The M4 positive allosteric modulator program is expected to enter the clinic by mid-2025[8]. Cash Position - The company had cash, cash equivalents, and marketable securities of $307.6 million as of December 31, 2024, expected to support operations into mid-2026[13]. Clinical Trials and Studies - The company has paused the KOASTAL-2 and -3 studies to optimize site selection and medical monitoring, with plans to resume in March 2025[4]. - Neumora discontinued the Phase 2 trial for navacaprant in bipolar depression to focus resources on the KOASTAL program[6].